文献速递泌尿男性生殖肿瘤

关于将前列腺特异性膜抗原正电子发射断层成像整合至临床前列腺癌试验的考量:国家临床试验网络合作组的共识

Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
PubMed 文献 · J Clin Oncol · 2022-01-11

美国国家癌症研究所临床影像指导委员会PSMA PET工作组召集多学科专家,于2021年4月至7月通过会议和匿名调查识别PSMA PET纳入前列腺癌临床试验的挑战,形成共识文件,就患者选择、终点定义、 eligibility标准和结果解读提供指导。

要点

  • PSMA PET灵敏度高于传统影像,导致分期迁移并影响试验患者选择和终点定义。
  • 共识文件就不同临床场景下的 eligibility 标准和结局指标定义提供指导与解决方案。
  • 文章为临床试验设计、实施及结果解读提供建议。

核心结论

  • 随着PSMA PET在美国日益普及,其相较传统影像的更高灵敏度给临床试验带来挑战,本共识文件就此提出指导。

研究设计与样本

  • 由NCI临床影像指导委员会(CISC)PSMA PET工作组召集临床医生、生物统计学家、患者倡导者及影像专家,于2021年4月至7月开会讨论并发放匿名开放式调查,经多轮反馈形成共识文件。

主要发现

  • 工作组识别了分期迁移、疗效评估、试验后勤和统计学等方面的挑战,并讨论了相应解决方案。
  • 共识文件概述了PSMA PET日益普及给前列腺癌临床试验带来的关键挑战,并讨论了其对患者选择和终点定义的影响。
  • 针对不同临床场景提供了指导与潜在解决方案,尤其涉及 eligibility 标准和结局指标定义的最佳实践。

关键数值与推荐

  • 文章就临床试验设计与实施以及试验结果解读提供指导。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As prostate-specific membrane antigen (PSMA) positron emission tomography (PET) becomes increasingly available in the United States, the greater sensitivity of the technology in comparison to conventional imaging poses challenges for clinical trials. The NCI Clinical Imaging Steering Committee (CISC) PSMA PET Working Group was convened to coordinate the identification of these challenges in various clinical scenarios and to develop consensus recommendations on how best to integrate PSMA PET into ongoing and upcoming National Clinical Trials Network (NCTN) trials. METHODS: NCI CISC and NCI Genitourinary Steering Committee members and leadership nominated clinicians, biostatisticians, patient advocates, and other imaging experts for inclusion in the PSMA PET Working Group. From April to July 2021, the working group met independently and in conjunction with the CISC to frame challenges, including stage migration, response assessment, trial logistics, and statistical challenges, and to discuss proposed solutions. An anonymous, open-ended survey was distributed to members to collect feedback on challenges faced. Representatives from each NCTN group were invited to present an overview of affected trials. From these discussions, the consensus document was developed and circulated for the inclusion of multiple rounds of feedback from both the Working Group and CISC. RESULTS: The current consensus document outlines the key challenges for clinical prostate cancer trials resulting from the increasing availability of PSMA PET. We discuss implications for patient selection and definition of end points and provide guidance and potential solutions for different clinical scenarios, particularly with regard to best practices in defining eligibility criteria and outcome measures. RECOMMENDATIONS: This article provides guidance regarding clinical trial design and conduct, and the interpretation of trial results.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schöder H, Hope TA, Knopp M, et al. Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. J Clin Oncol. 2022. PMID: 35015566. doi:10.1200/JCO.21.02440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。